Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GRAIL Inc ( (GRAL) ) has provided an update.
On Feb. 19, 2026, GRAIL reported that 2025 total revenue rose 17% year on year to $147.2 million, driven by a 26% increase in U.S. Galleri sales to $136.8 million, while net loss narrowed sharply to $408.4 million and adjusted EBITDA improved 34%. The company sold more than 185,000 Galleri tests in 2025, ended the year with $904.4 million in cash and securities, and said its balance sheet supports operations into 2030.
GRAIL also announced top-line results from the large randomized NHS-Galleri trial in England, where adding Galleri to standard cancer screening did not achieve the primary endpoint of statistically reducing combined Stage III–IV cancers but did substantially cut Stage IV diagnoses and increase early Stage I–II detection. The company completed analysis of the 35,000-participant PATHFINDER 2 study with performance consistent with earlier data, finished the final module of its FDA premarket approval submission for Galleri in January, and stands to benefit from new U.S. federal law establishing a Medicare coverage pathway for multi-cancer early detection tests.
The most recent analyst rating on (GRAL) stock is a Hold with a $114.00 price target. To see the full list of analyst forecasts on GRAIL Inc stock, see the GRAL Stock Forecast page.
Spark’s Take on GRAL Stock
According to Spark, TipRanks’ AI Analyst, GRAL is a Neutral.
The score is driven by strong technical momentum and constructive earnings-call updates (growth, improving efficiency, and extended cash runway). This is tempered by weak financial performance today—material losses and ongoing cash burn—and a valuation profile constrained by negative earnings.
To see Spark’s full report on GRAL stock, click here.
More about GRAIL Inc
GRAIL, Inc. is a U.S.-based healthcare company focused on early cancer detection, using next-generation sequencing, large clinical studies, and machine learning to identify multiple deadly cancers at earlier stages. Its flagship product, the Galleri multi-cancer early detection blood test, targets adults at elevated cancer risk and is sold primarily in the U.S., with growing access through digital health platforms and health system partnerships.
GRAIL’s technology platform supports screening and precision oncology applications, including risk stratification, minimal residual disease detection, and treatment monitoring. Headquartered in Menlo Park, Calif., with additional sites in Washington, D.C., North Carolina, and the U.K., the company is listed on Nasdaq under the ticker GRAL and is positioning Galleri as a leading multi-cancer early detection test in a rapidly emerging market segment.
Average Trading Volume: 863,434
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.86B
For detailed information about GRAL stock, go to TipRanks’ Stock Analysis page.